Multicenter prospective observational study of dupilumab‐induced ocular events in atopic dermatitis patients
Journal of the European Academy of Dermatology and Venereology · 2023-05 · 37 (5) · 1056-1063
DOI: 10.1111/jdv.18932 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 16.02.2023. Verfasst von Ingrid Costedoat und 32 weiteren Autor:innen. Beteiligte Einrichtung: CHU de Bordeaux, National Reference Center for Rare Skin Diseases, CNRS UMR5164, ImmunoConCept, Univ. Bordeaux, Bordeaux, France. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Conjunctivitis. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Background
Although ocular adverse events are frequent in AD patients treated with dupilumab, their characterization remains limited due to a lack of prospective studies with a systematic ophthalmological examination.
Objective
To examine the incidence, characteristics and risk factors of dupilumab‐induced ocular adverse events.
Methods
A prospective, multicenter, and real‐life study in adult AD patients treated with dupilumab.
Results
At baseline, 27 out of 181 patients (14.9%) had conjunctivitis. At week 16 (W16), 25 out of 27 had improved their conjunctivitis and 2 remained stable and 34 out of 181 patients (18.7%) had dupilumab‐induced blepharoconjunctivitis: either de novo ( n = 32) or worsening of underlying blepharoconjunctivitis ( n = 2). Most events (27/34; 79.4%) were moderate. A multivariate analysis showed that head and neck AD (OR = 7.254; 95%CI [1.938–30.07]; p = 0.004), erythroderma (OR = 5.635; 95%CI [1.635–21.50]; p = 0.007) and the presence of dry eye syndrome at baseline (OR = 3.51; 95%CI [3.158–13.90]; p = 0.031) were independent factors associated with dupilumab‐induced blepharoconjunctivitis.
Limitations
Our follow‐up period was 16 weeks and some late‐onset time effects may still occur.
Conclusion
This study showed that most dupilumab‐induced blepharoconjunctivitis cases are de novo. AD severity and conjunctivitis at baseline were not found to be associated risk factors in this study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- CHU de Bordeaux, National Reference Center for Rare Skin Diseases, CNRS UMR5164, ImmunoConCept, Univ. Bordeaux, Bordeaux, France.
- Department of Dermatology and Ophthalmology, CHU Nantes, UMR 1280 PhAN, INRA, Nantes Université, Nantes, France.
- CHU Nantes, Direction de la recherche, Plateforme de Méthodologie et Biostatistique, Nantes Université, Nantes, France.
- Department of Dermatology-Venerology, CHU Robert-Debré, Reims, France.
- Department of Ophthalmology, CHU Robert-Debré, Reims, France.
- Department of Dermatology-Venerology and Ophthalmology, Centre Hospitalier Universitaire Clermont-Ferrand, Clermont-Ferrand, France.
ORCID-Profile: Ingrid Costedoat, Marie Lamiaux, Marie Tauber, Marie Jachiet, Frederic Dezoteux, Angele Soria, Julien Seneschal, Sebastien Barbarot
Zitieren
APA
Costedoat, I., Wallaert, M., Gaultier, A., Vasseur, R., Vanhaecke, C., Viguier, M., Cordelette, C., Denoyer, A., Ferrier le Bouëdec, M. C., Coutu, A., Lamiaux, M., Tran, T. H. C., Lacour, J. P., Elmaleh, V., Tetart, F., Gueudry, J., Tauber, M., Giordano-Labadie, F., Cassagne, M., …, & FRench Atopic DErmatitis Network from the Groupe de Recherche sur l'Eczema Atopique (GREAT), France (2023). Multicenter prospective observational study of dupilumab‐induced ocular events in atopic dermatitis patients. Journal of the European Academy of Dermatology and Venereology, 37(5), 1056-1063. https://doi.org/10.1111/jdv.18932
Vancouver
Costedoat I, Wallaert M, Gaultier A, Vasseur R, Vanhaecke C, Viguier M, et al. Multicenter prospective observational study of dupilumab‐induced ocular events in atopic dermatitis patients. Journal of the European Academy of Dermatology and Venereology. 2023;37(5):1056-1063. doi:10.1111/jdv.18932
BibTeX
@article{Costedoat2023,
author = {Costedoat, Ingrid and Wallaert, Martin and Gaultier, Aurelie and Vasseur, Robin and Vanhaecke, Clelia and Viguier, Manuelle and Cordelette, Charles and Denoyer, Alexandre and Ferrier le Bouëdec, Marie-Christine and Coutu, Adrien and Lamiaux, Marie and Tran, Thi Ha Châu and Lacour, Jean Philippe and Elmaleh, Valerie and Tetart, Florence and Gueudry, Julie and Tauber, Marie and Giordano-Labadie, Francoise and Cassagne, Myriam and Nosbaum, Audrey and Ouilhon, Coralie and Jachiet, Marie and Tadayoni, Ramin and Dezoteux, Frederic and Staumont-Salle, Delphine and Bouleau, Julien and Labalette, Pierre and Doan, Serge and Soria, Angele and Mortemousque, Bruno and Seneschal, Julien and Barbarot, Sebastien and FRench Atopic DErmatitis Network from the Groupe de Recherche sur l'Eczema Atopique (GREAT), France, FRench Atopic DErmatitis Network from the Groupe de Recherche sur l'Eczema Atopique (GREAT), France},
title = {Multicenter prospective observational study of dupilumab‐induced ocular events in atopic dermatitis patients},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2023},
volume = {37},
number = {5},
pages = {1056--1063},
doi = {10.1111/jdv.18932}
}
EUVIMED